Zhang Mingliang, Guo Wei, Qian Jun, Wang Benzhong
Department of Breast Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province 230032, China.
J Cancer Res Ther. 2015 Aug;11 Suppl 1:C125-7. doi: 10.4103/0973-1482.163868.
The aim of this retrospectively study was to assess the clinical efficacy and toxicity of Herceptin as a single agent in the treatment of patients with metastatic breast cancer (MBC).
We retrospectively included and analyzed 31 metastasis breast cancer patients in our patient database. All of the included 31 patients were pathology confirmed of breast carcinoma with remote metastases and treated with Herceptin as a single agent. The clinical efficacy and drug-related toxicity were analyzed.
No complete response patients were observed for 31 cases. And 8 (26%) reached partial response 16 (52%) with stable disease. The objective response rate of the 31 patients was 23%. We further divided the 31 cases into three subgroups according to the treatment modality. The objective response rate was 36%, 14%, and 17% for the first-line, second-line, and third-line treatment modality, respectively. The objective response rate was not statistical different among the three subgroups (P > 0.05). The main drug-related adverse event were asthenia, chills, diarrhea, nausea, hypotension and dizziness with their incidence of 68%, 26%, 13%, 10%, 10%, and 6%, respectively, for each patients.
Herceptin as a single agent was effective and safe in the treatment of patients with MBC.
本回顾性研究旨在评估赫赛汀单药治疗转移性乳腺癌（MBC）患者的临床疗效和毒性。
我们回顾性纳入并分析了患者数据库中的31例转移性乳腺癌患者。纳入的31例患者均经病理证实为伴有远处转移的乳腺癌，并接受了赫赛汀单药治疗。分析了临床疗效和药物相关毒性。
31例患者均未观察到完全缓解。8例（26%）达到部分缓解，16例（52%）病情稳定。31例患者的客观缓解率为23%。我们根据治疗方式将31例患者进一步分为三个亚组。一线、二线和三线治疗方式的客观缓解率分别为36%、14%和17%。三个亚组之间的客观缓解率无统计学差异（P>0.05）。主要的药物相关不良事件为乏力、寒战、腹泻、恶心、低血压和头晕，每位患者的发生率分别为68%、26%、13%、10%、10%和6%。
赫赛汀单药治疗MBC患者有效且安全。
